Nkarta (NKTX) Retained Earnings (2019 - 2026)
Nkarta's quarterly Retained Earnings came in at -$676.1 million in Q1 2026, down 17.34% year-on-year from -$818.0 million in Q1 2025, and down 4.29% quarter-over-quarter from -$648.3 million in Q4 2025.
Nkarta has reported Retained Earnings for 8 years, with the latest figure at -$676.1 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 17.34% year-over-year to -$676.1 million; the trailing twelve-month figure through Mar 2026 stood at -$676.1 million (down 17.34% YoY), and the FY2025 full-year result was -$648.3 million, down 96288.13% from the prior year.
- Retained Earnings for Q1 2026 stood at -$676.1 million, down from -$648.3 million in the prior quarter.
- The five-year high for Retained Earnings was $674000.0 in Q4 2024, with the low at -$676.1 million in Q1 2026.
- Average Retained Earnings over 5 years is -$358.9 million, with a median of -$407.7 million recorded in 2023.
- Year-over-year, Retained Earnings slumped 676864.71% in 2022 and surged 100.15% in 2024.
- Tracing NKTX's Retained Earnings over 5 years: stood at -$679000.0 in 2022, then tumbled by 64028.72% to -$435.4 million in 2023, then jumped by 100.15% to $674000.0 in 2024, then plunged by 96288.13% to -$648.3 million in 2025, then retreated by 4.29% to -$676.1 million in 2026.
- The last three Retained Earnings figures came in at -$676.1 million (Q1 2026), -$648.3 million (Q4 2025), and -$620.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | -676.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -676.14 Mn |
| Dec 31, 2025 | -648.31 Mn |
| Sep 30, 2025 | -620.90 Mn |
| Jun 30, 2025 | -599.20 Mn |
| Mar 31, 2025 | -576.20 Mn |
| Dec 31, 2024 | 674,000.00 |
| Sep 30, 2024 | -518.29 Mn |
| Jun 30, 2024 | -263,000.00 |
| Mar 31, 2024 | -465.00 Mn |
| Dec 31, 2023 | -435.43 Mn |
| Sep 30, 2023 | -407.68 Mn |
| Jun 30, 2023 | -382.04 Mn |
| Mar 31, 2023 | -174,000.00 |
| Dec 31, 2022 | -679,000.00 |
| Sep 30, 2022 | -285.40 Mn |
| Jun 30, 2022 | -257.00 Mn |
| Mar 31, 2022 | -230.10 Mn |
| Dec 31, 2021 | -204.10 Mn |
| Sep 30, 2021 | -181.28 Mn |
| Jun 30, 2021 | -158.90 Mn |
| Mar 31, 2021 | 34,000.00 |
| Dec 31, 2020 | 3,000.00 |
| Sep 30, 2020 | -100.12 Mn |
| Jun 30, 2020 | -86.43 Mn |
| Dec 31, 2019 | -2,000.00 |